AR008982A1 - Procedimiento para la preparacion de un material antigenico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacaridos y/o glicopeptidos (asmp, anmp o aemp), dicho material antigenico, y su uso, vacuna y solucion inyectable a base del material antigenico, metodo que lo emplea - Google Patents

Procedimiento para la preparacion de un material antigenico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacaridos y/o glicopeptidos (asmp, anmp o aemp), dicho material antigenico, y su uso, vacuna y solucion inyectable a base del material antigenico, metodo que lo emplea

Info

Publication number
AR008982A1
AR008982A1 ARP960103948A AR10394896A AR008982A1 AR 008982 A1 AR008982 A1 AR 008982A1 AR P960103948 A ARP960103948 A AR P960103948A AR 10394896 A AR10394896 A AR 10394896A AR 008982 A1 AR008982 A1 AR 008982A1
Authority
AR
Argentina
Prior art keywords
soluble
antigenic
antigenic material
preparation
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP960103948A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AR008982A1 publication Critical patent/AR008982A1/es
Anticipated expiration legal-status Critical
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/72—Candida
    • C12R2001/725—Candida albicans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/921—Candida
    • Y10S435/922—Candida albicans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procedimiento para la preparacion de un material antigénico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacáridos y/oglicopéptidos (ASMP, ANMP o AEMP), en el que se usan células fungicas que pertenecen al grupode hongos queratinofílicos o levaduras o un material delas mismas. El material antigénico obtenido tiene actividad antialérgica en mamíferos. Dicho material es util para la preparacion de productosfarmacéuticos destinado al tratamiento dealergia, así como modular la respuesta inmunologica, y de vacunas y soluciones para inyeccion. Elmicroorganismo Candida albicans (DSM N* 9656) y mutantes del mismo tienen baja patogenicidad y proveen dicho material antigénico.
ARP960103948A 1995-08-11 1996-08-12 Procedimiento para la preparacion de un material antigenico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacaridos y/o glicopeptidos (asmp, anmp o aemp), dicho material antigenico, y su uso, vacuna y solucion inyectable a base del material antigenico, metodo que lo emplea Suspension/Interruption AR008982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516461A GB2304347A (en) 1995-08-11 1995-08-11 Antigenic preparations

Publications (1)

Publication Number Publication Date
AR008982A1 true AR008982A1 (es) 2000-03-08

Family

ID=10779086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103948A Suspension/Interruption AR008982A1 (es) 1995-08-11 1996-08-12 Procedimiento para la preparacion de un material antigenico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacaridos y/o glicopeptidos (asmp, anmp o aemp), dicho material antigenico, y su uso, vacuna y solucion inyectable a base del material antigenico, metodo que lo emplea

Country Status (25)

Country Link
US (2) US6379678B1 (es)
EP (1) EP0863991B1 (es)
JP (3) JP4285768B2 (es)
KR (1) KR100447926B1 (es)
CN (1) CN1228450C (es)
AR (1) AR008982A1 (es)
AT (1) ATE253641T1 (es)
AU (1) AU717731B2 (es)
CA (1) CA2229203C (es)
CO (1) CO4750671A1 (es)
CZ (1) CZ294394B6 (es)
DE (1) DE69630611T2 (es)
DK (1) DK0863991T3 (es)
ES (1) ES2206588T3 (es)
GB (1) GB2304347A (es)
HU (1) HU224223B1 (es)
IL (1) IL123153A (es)
MX (1) MX9801180A (es)
NZ (1) NZ316062A (es)
PL (1) PL186523B1 (es)
PT (1) PT863991E (es)
RU (1) RU2245721C2 (es)
SK (1) SK282746B6 (es)
WO (1) WO1997007232A1 (es)
ZA (1) ZA966801B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020959C1 (ru) * 1991-10-21 1994-10-15 Игорь Дмитриевич Поляков Вакцина поливак-тм для профилактики и лечения дерматофитозов животных
GB2304347A (en) * 1995-08-11 1997-03-19 Boeringer Ingelheim Vetmedica Antigenic preparations
EP0834322A3 (en) * 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mycosis vaccine
WO1999049876A2 (en) * 1998-03-31 1999-10-07 Abbott Laboratories Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof
CA2325063A1 (en) * 2000-10-27 2002-04-27 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Method for detecting antibodies to and antigens of fungal and yeast exposures
KR101241272B1 (ko) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
WO2010032139A1 (en) * 2008-09-17 2010-03-25 Hunter Immunology Limited Bacterial and fungal vaccines for the treatment of asthma
RU2660365C1 (ru) * 2015-11-20 2018-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения специфических антигенных препаратов из клинически значимых дрожжевых грибов
ES2878071T3 (es) 2016-03-15 2021-11-18 Igor Polyakov Nuevos productos inmunobiológicos
AU2017234985B2 (en) * 2016-03-15 2023-10-12 Liudmila IVANOVA Compositions for the treatment and prevention of hoof and claw diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867555A (en) * 1972-11-29 1975-02-18 Anheuser Busch Manufacture of yeast protein isolate having a reduced nucleic acid content by an alkali process
GB1541511A (en) * 1976-01-19 1979-03-07 Idemitsu Kosan Co Polysaccharide and process for the production thereof
JPS536413A (en) * 1976-07-07 1978-01-20 Kureha Chem Ind Co Ltd Preparation of n-containing polysaccharides
NO153458C (no) * 1978-06-07 1986-03-26 Inst Experimentalnoi Veterinar Fremgangsm¨te for fremstilling av vaksine for profylakse o g behandling av ringorm hos pelsdyr og kaniner for¨rsaket av trichophyton mentagrophytes.
AU547928B2 (en) * 1981-11-03 1985-11-14 Sutka, K. Antigenic preparation from candida guilliermondii
GB8506373D0 (en) * 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
AU7761091A (en) 1990-04-09 1991-10-30 Adalbert Kopera Antenna assembly
US5277904A (en) * 1990-10-26 1994-01-11 Pier Allan C Broad spectrum dermatophyte vaccine
RU2020959C1 (ru) 1991-10-21 1994-10-15 Игорь Дмитриевич Поляков Вакцина поливак-тм для профилактики и лечения дерматофитозов животных
EP0714412A1 (en) 1993-08-19 1996-06-05 Minnesota Mining And Manufacturing Company Heparin functional affinity supports
AUPM473294A0 (en) * 1994-03-25 1994-04-21 Franklyn, Kathleen Mary Peptides for diagnostics and therapeutics
GB2304347A (en) 1995-08-11 1997-03-19 Boeringer Ingelheim Vetmedica Antigenic preparations
EP0834322A3 (en) 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mycosis vaccine

Also Published As

Publication number Publication date
NZ316062A (en) 1998-12-23
JP2008266352A (ja) 2008-11-06
CZ294394B6 (cs) 2004-12-15
PL324975A1 (en) 1998-06-22
MX9801180A (es) 1998-04-30
JP4286312B2 (ja) 2009-06-24
AU6820796A (en) 1997-03-12
GB2304347A (en) 1997-03-19
WO1997007232A1 (en) 1997-02-27
US7090857B2 (en) 2006-08-15
SK17798A3 (en) 1998-07-08
CZ40098A3 (cs) 1998-07-15
CN1199426A (zh) 1998-11-18
CN1228450C (zh) 2005-11-23
CA2229203A1 (en) 1997-02-27
JP4286311B2 (ja) 2009-06-24
ZA966801B (en) 1997-03-14
PL186523B1 (pl) 2004-01-30
DE69630611T2 (de) 2004-06-03
IL123153A (en) 2002-05-23
EP0863991A1 (en) 1998-09-16
US20040071737A1 (en) 2004-04-15
HUP9802419A2 (hu) 1999-02-01
SK282746B6 (sk) 2002-12-03
KR100447926B1 (ko) 2004-11-09
HU224223B1 (hu) 2005-06-28
GB9516461D0 (en) 1995-10-11
ATE253641T1 (de) 2003-11-15
CO4750671A1 (es) 1999-03-31
US6379678B1 (en) 2002-04-30
HUP9802419A3 (en) 1999-12-28
CA2229203C (en) 2011-12-13
DK0863991T3 (da) 2004-02-09
DE69630611D1 (de) 2003-12-11
AU717731B2 (en) 2000-03-30
JP4285768B2 (ja) 2009-06-24
KR19990036326A (ko) 1999-05-25
JP2008245658A (ja) 2008-10-16
EP0863991B1 (en) 2003-11-05
IL123153A0 (en) 1998-09-24
PT863991E (pt) 2004-01-30
RU2245721C2 (ru) 2005-02-10
ES2206588T3 (es) 2004-05-16
JPH11511019A (ja) 1999-09-28

Similar Documents

Publication Publication Date Title
AR008982A1 (es) Procedimiento para la preparacion de un material antigenico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacaridos y/o glicopeptidos (asmp, anmp o aemp), dicho material antigenico, y su uso, vacuna y solucion inyectable a base del material antigenico, metodo que lo emplea
AR005583A1 (es) Una composicion para el tratamiento de la celulitis mediante aplicacion topica, un metodo de tratamiento cosmetico para lograr un efecto adelgazante y un metodo de tratamietno cosmetico para atenuar el aspecto adiposo, de "cascara de naranja" de la piel
SE9404020L (sv) Mannanasenzymer, gener kodande för dem, metoder a tt isolera generna, och metoder för blekning av lignocellulosamassor
CA2366065A1 (en) Topical cosmetic composition comprising bifidobacterium and plant extracellular matrix
GB9323588D0 (en) Hydrophobic preparation
ES2059674T3 (es) Uso de una composicion como un producto cosmetico.
NO915116D0 (no) Ikke-glykosylerte human-interleukin-3-analogproteiner
ATE118788T1 (de) Antifungisches polypeptid, verfahren zu seiner herstellung.
ES2068797T3 (es) Producto para el tratamiento del cabello y procedimiento para su aplicacion.
WO2009017462A3 (en) New ganoderma tsugae var. jannieae strain tay-i and biologically active biomass and extracts therefrom
ATE151643T1 (de) Lanolinderivate als penetrationsfördernde substanzen
AR015230A1 (es) Composicion cosmetica que contiene un compuesto de actividad estimuladora de la produccion de interleuquina-6, cepa rhodotorula sebr 2002, procedimiento depreparacion de un extracto, composicion obtenida, utilizacion de un compuesto de actividad estimuladora y metodo de tratamiento cosmetico.
HK1041219A1 (en) Mucosal delivery system
EP0547102A4 (es)
ES2163449T3 (es) Preparado oxigenado funcional que contiene fosfolipidos y fluorocarbono.
SE9003311L (sv) Anvaendning av glykoproteiner, utvunna fraan gram (-) bakterier, foer tillverkning av kosmetiska eller dermatologiska kompositioner och kompositioner omfattande dessa glykoproteiner
AU667338B2 (en) Melanin decomposing method and melanin decomposing substance
ATE15072T1 (de) Verfahren zur gewinnung anaboler, atmungsfoerdernder, niedermolekularer wirkstoffe fuer prophylaktische, therapeutische, zell- und gewebekulturtechnische zwecke.
ES2104686T3 (es) Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.
BG100992A (en) A ranitidine tablet having a hydroxypropylmethylcellulose containing coating and a method for producing said coating
ATE136783T1 (de) Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
JPS6442412A (en) Skin-beautifying cosmetic
AU6309096A (en) Aqueous insecticide and pesticide composition, method of production and use thereof
GB1083277A (en) Process for the isolation of polysaccharides and lipopolysaccarides having antigenicactivity

Legal Events

Date Code Title Description
FB Suspension of granting procedure